Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Tivozanib in Refractory Metastatic Colorectal Cancer
NCT01058655Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2010
- Primary completion
- Sep 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, tivozanib in colorectal cancer (CRC), gastrointestinal cancer, sponsored by Dana-Farber Cancer Institute. Started Feb 2010; status: completed.
02
Drugs
everolimustivozanib
03
Conditions
colorectal cancer (CRC)gastrointestinal cancer
Beyond the preview
Go deeper on NCT01058655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058655.